Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI (PIXCIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03438357
Recruitment Status : Active, not recruiting
First Posted : February 19, 2018
Last Update Posted : January 27, 2020
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes

Brief Summary:
Using an automatic software tool, Pixyl.Neuro, to conduct a retrospective analysis (detection of lesions + segmentation of images + tracking over time) of cerebral MRI images acquired during a prospective study of patients presenting with clinically isolated syndrome, and comparing the results against manual analysis.

Condition or disease Intervention/treatment
Multiple Sclerosis Clinically Isolated Syndrome Other: Analysis of cerebral MRI with automatic segmentation software

Layout table for study information
Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI
Actual Study Start Date : January 2, 2019
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients with multiple sclerosis Other: Analysis of cerebral MRI with automatic segmentation software
Pixyl.Neuro software versus manual analysis of lesions




Primary Outcome Measures :
  1. Lesions detected by Pixyl.Neuro software that were missed by manual analysis of MRI images follow-up images compared to reference image (new T2 lesions, enlarging T2 lesions, new T1 gadolinium lesions) [ Time Frame: baseline until follow-up (maximum 2 years) ]
    % cases


Secondary Outcome Measures :
  1. Inter-reader reproducibility [ Time Frame: baseline until follow-up (maximum 2 years) ]
    DICE similarity coefficient between readers

  2. Software versus manual analysis reproducibility for same reader [ Time Frame: baseline until follow-up (maximum 2 years) ]
    DICE similarity coefficient between software result and manual result

  3. Classification of discordances [ Time Frame: baseline until follow-up (maximum 2 years) ]
    Specific description of missed lesions according to technology at fault



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 56 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subset of patient data collected for the project D-Lay-MS: NCT01817166
Criteria

Identical to those of the study D-Lay-MS: NCT01817166:

Inclusion Criteria:

  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 24 months of follow-up
  • The patient has had a classic CIS with the past 90 days
  • Reference cerebro-medullary MRI scheduled within the 90 days after the beginning of symptoms
  • With MRI (cerebro ± medullary) showing demyelination according to spatial spread criteria by Swanton (2006):
  • At least 1 lesion in at least 2 of the 4 following territories: (1) Peri-ventricular; (2) Juxta-cortical; (3) Sub-tentorial; (4) Medullary
  • No other suspected pathology
  • Vitamin D level in blood less than 100 nmol / l at the pre-inclusion visit
  • Women of childbearing potential must use very effective contraception for the duration of the study. A very effective contraceptive method is defined as a method resulting in a low failure rate (that is to say less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, IUDs, sexual abstinence, or partner with a vasectomy.

Randomisation stratification criteria:

• The patient can also also meet the temporal dissemination criteria defined according to McDonald criteria 2010 (Polman et al., 2011), because this condition is currently not sufficient for prescribing a background treatment: Simultaneous presence of at least one asymptomatic lesion taking on contrast and at least one asymptomatic lesion not taking on contrast after injection of gadolinium

Exclusion Criteria:

  • The patient is participating in another study other than D-Lay-MS: NCT01817166 (this criteria does not apply to the POLAR study (RCB 2011-A01269-32); patients included in this study may simultaneously participate in the POLAR study)
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant, parturient, or breastfeeding
  • Major medical or psychiatric illness that, according to the investigator, would result in the patient running an unnecessary risk or that could affect compliance with the study protocol
  • Vitamin D insufficiency linked to currently active digestive or more general diseases (celiac disease, inflammatory bowel disease, intestinal bypass, short bowel syndrome, cirrhosis, nephrotic syndrome, hyperthyroidism, rickets, hypoparathyroidism, cancer, granulomatous diseases and lymphomas)
  • Moderate or severe renal insufficiency (creatinine clearance less than 60 ml / min)
  • Epilepsy not adequately controlled by treatment
  • Any illness requiring chronic treatment with corticosteroids
  • Patient with osteoporosis or history of osteopenia
  • Pathology requiring calcium intakes greater than 1 gram per day
  • Current or past history of hypercalcemia
  • Medications that affect the metabolism of vitamin D other than corticosteroids; e.g. anticonvulsants [phenobarbital, primidone, phenytoin] rifampicin, isoniazid, ketoconazole, 5-FU and leucovorin, thiazide diuretics.
  • Situations accompanied by increased vulnerability to hypercalcemia, e.g. arrhythmia or known heart disease, treatment with digitalis, and subjects with nephrolithiasis.
  • Contraindications to vitamin D3 as mentioned in the documentation for UVEDOSE
  • Known hypersensitivity to gadolinium and / or known inability to undergo an MRI (pacemaker, osteosynthesis material, intraocular metal splinter, etc ....).
  • The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
  • The subject refuses to sign the consent
  • It is impossible to give the subject informed information
  • The patient is under safeguard of justice or state guardianship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03438357


Locations
Layout table for location information
France
CHU Nimes
Nîmes, France, 30029
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nīmes
Roche Pharma AG
Investigators
Layout table for investigator information
Principal Investigator: Eric Thouvenot CHU Nimes
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier: NCT03438357    
Other Study ID Numbers: IDIL/2017/ET-01
First Posted: February 19, 2018    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases